Michelle Vu
Cedars-Sinai Medical Center
13 Papers
27 Citations
Michelle Vu is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Diverticulitis & Cathelicidin. The author has an hindex of 6, co-authored 13 publications.
Chat about Author
Papers
Increased Risk for Irritable Bowel Syndrome After Acute Diverticulitis
Erica R. Cohen,Garth Fuller,Roger Bolus,Rusha Modi,Michelle Vu,Kamyar Shahedi,Rena Shah,Mary A. Atia,Nicole Kurzbard,Victoria Sheen,Nikhil Agarwal,Marc Kaneshiro,Linnette Yen,Paul Hodgkins,M. Haim Erder,Brennan Spiegel +15 more
TL;DR: DiverticULitis appears to predispose patients to long-term gastrointestinal and emotional symptoms after resolution of inflammation; in this way, postdiverticulitis IBS is similar to postinfectious IBS.
117
Constitutive TL1A Expression under Colitogenic Conditions Modulates the Severity and Location of Gut Mucosal Inflammation and Induces Fibrostenosis
Robert Barrett,Xiaolan Zhang,Xiaolan Zhang,Hon Wai Koon,Michelle Vu,Jyh-Yau Chang,Nicole Yeager,Mary Ann Nguyen,Kathrin S. Michelsen,Dror Berel,Charalabos Pothoulakis,Stephan R. Targan,David Q. Shih +12 more
TL;DR: Data show that TL1A is an important cytokine that not only modulates the location and severity of mucosal inflammation, but also induces fibrostenosis.
92
Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor.
D Hoang-Yen Tran,D Hoang-Ngoc Tran,S A Mattai,Tamer Sallam,Christina Ortiz,Elaine C. Lee,Lori Robbins,Samantha Ho,Jung Eun Lee,E Fisseha,Christine Shieh,Aristea Sideri,David Q. Shih,Philip Fleshner,Dermot P.B. McGovern,Michelle Vu,Tressia C. Hing,Kyriaki Bakirtzi,Michelle Cheng,Bowei Su,Ivy Ka Man Law,Iordanes Karagiannides,Stephan R. Targan,Richard L. Gallo,Zhaoping Li,Hon Wai Koon +25 more
TL;DR: It is demonstrated that cathelicidin modulates the development of obesity by inhibits the CD36 fat receptor and lipid accumulation in adipocytes and hepatocytes, leading to a reduction of fat mass and hepatic steatosis in vivo.
847 Progression From Incidental Diverticulosis to Acute Diverticulitis
Kamyar Shahedi,Garth Fuller,Roger Bolus,Bradley J. Snyder,Erica R. Cohen,Michelle Vu,Rena Shah,Rusha Modi,Mary A. Atia,Nicole Kurzbard,Victoria Sheen,Nikhil Agarwal,Marc Kaneshiro,Linnette Yen,Paul Hodgkins,Moshe H. Erder,Poyrung Poysophon,Brennan Spiegel +17 more
17
CSA13 inhibits colitis-associated intestinal fibrosis via a formyl peptide receptor like-1 mediated HMG-CoA reductase pathway.
Chunlan Xu,Chunlan Xu,Sally Ghali,Jiani Wang,Jiani Wang,David Q. Shih,Christina Ortiz,Caroline C. Mussatto,Elaine C. Lee,Diana H. Tran,Jonathan P. Jacobs,Venu Lagishetty,Phillip Fleshner,Lori Robbins,Michelle Vu,Tressia C. Hing,Dermot P.B. McGovern,Hon Wai Koon +17 more
TL;DR: Many Crohn’s disease patients develop intestinal strictures, which are difficult to prevent and treat, and it is hypothesized that CSA13 mediates anti-fibrogenic effects via FPRL1, which is associated with severe mucosal disease activity and intestinal stricture.